Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + hs-10352
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Fulvestrant + HS-10352 is a combination therapy being investigated for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer harboring PIK3CA mutations. HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase alpha (PI3Kα/p110α) with an IC50 value of 0.34 nM. It exhibits 321-fold, 103-fold, and 159-fold higher selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. This heightened selectivity may help minimize severe side effects commonly associated with inhibition of other PI3K isoforms. Fulvestrant is an estrogen receptor antagonist administered intramuscularly. The combination shows synergistic anticancer effects, as fulvestrant can enhance the sensitivity of estrogen receptor-positive tumors to PI3Kα inhibition.
02
Targets
ER (Estrogen receptor)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on fulvestrant + hs-10352.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + hs-10352.